There is growing interest in pharmacoeconomic principles across the Middle East and Africa region. The reason for this is in line with global trends, the region is facing a continuous increase in medical costs and a surge in disease prevalence. Health stakeholders are therefore more sensitive to the economic impact of new therapies.